Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,669 recruiting studies in this area right now.
By phase
- Not applicable9,830
- Phase 24,462
- Phase 12,741
- Phase 1/Phase 21,687
- Phase 31,405
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer659
- Prostate Cancer657
- Colorectal Cancer496
- Lung Cancer428
- Ovarian Cancer338
- Multiple Myeloma329
- Gastric Cancer300
- Pancreatic Cancer296
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer232
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors195
- Esophageal Cancer193
Leading sponsors
- M.D. Anderson Cancer Center451
- Fudan University311
- Memorial Sloan Kettering Cancer Center289
- Sun Yat-sen University289
- National Cancer Institute (NCI)288
- Mayo Clinic238
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto125
Where studies are running
- California1,425
- Texas641
- Arizona513
- Florida446
- Alabama420
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania241
Recruiting studies20,669 total
- NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT05263050RecruitingPhase 2
Trial tests a new cabozantinib schedule for kidney and neuroendocrine tumors
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05263570Recruiting
Real-world treatment planning for stage II–III HR+ HER2+ breast cancer
This trial looks at how well a standard “neoadjuvant” treatment plan works in real-world patients. It is for people newly diagnosed with stage II–III HR+ breast cancer and aims to see whether treatment gives expected outcomes in everyday care.
Shenyang, LiaoningAges 18 years+ - NCT05263830Recruiting
Testing Glypican-3 to predict outcomes in liver cancer immunotherapy
This study looks at a blood/tissue marker called Glypican-3 to see who is more likely to do well when treated with immunotherapy for liver cancer. It may help doctors predict outcomes and tailor future care.
ParisAges 18–90 - NCT05264337Recruiting
Study for swelling after prostate or other urinary surgery
This study looks at swelling caused by lymph fluid buildup after urinary (urologic) surgery that removes lymph nodes. If you’re scheduled for or recently had this type of surgery, this trial may help researchers understand how to prevent or treat this swelling.
GothenburgAges 18 years+ - NCT05264896RecruitingPhase 3
Stomach cancer surgery plus two chemo plans
This trial compares two chemotherapy schedules around stomach cancer surgery: giving chemo before and after surgery (FLOT) versus giving chemo after surgery (XELOX). It’s meant to see which plan works better and is easier to tolerate for locally advanced disease that has not spread.
Hong KongAges 18 years+ - NCT05264857Recruiting
Decision aid for managing suspicious thyroid nodules
This trial studies a decision-support tool to help people make choices about care for thyroid nodules that look indeterminate to cancer on biopsy. It may help you understand options and decide next steps more confidently.
Stony Brook, New YorkAges 18 years+ - NCT05265429Recruiting
Study of young people’s lung cancer biology
This study looks at biological samples from people diagnosed with lung cancer at age 45 or younger. It may help researchers understand how young lung cancers differ, which could guide future treatments.
Boston, MassachusettsAges 15 years+ - NCT05266612RecruitingPhase 1
Testing a cancer medicine for advanced solid tumors with HSV
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
Gilbert, ArizonaAges 18 years+ - NCT05266534Recruiting
Terlipressin or oxytocin during open fibroid surgery
This trial compares two injected medicines (terlipressin vs carbetocin) given into the uterus during open fibroid (myomectomy) surgery to see which one reduces blood loss and helps maintain hemoglobin. It may help patients by targeting lower bleeding during surgery.
MaadiAges 16–40 - NCT05266846RecruitingPhase 2
Immunotherapy plus anti-angiogenesis and chemo for ALK lung cancer
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
Changsha, HunanAges 18 years+ - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT05267041Recruiting
Lung cancer database study at Lyon hospitals
This study collects information about people who have been treated for lung or chest cancers at Lyon University Hospital. Your data may help researchers better understand these cancers and improve future care.
Pierre-BéniteAges 18 years+ - NCT05268614RecruitingPhase 2
Risk-based reduced chemo and radiation for HPV throat cancer
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
Gainesville, FloridaAges 18 years+ - NCT05269485RecruitingPhase 1/Phase 2
Hypofractionated radiation for stage III lung cancer
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Hefei, AnhuiAges 18–70 - NCT05271292RecruitingPhase 1/Phase 2
Chiauranib for advanced cancers that returned or won’t respond
This Phase 1/2 study tests chiauranib in people with advanced solid cancers (including small cell lung cancer) that have come back or no longer respond to standard treatments. It aims to find a safe dose and see whether the treatment can help shrink tumors.
Encinitas, CaliforniaAges 18 years+ - NCT05269316RecruitingPhase 1/Phase 2
Early-phase study of IMP9064 for advanced solid tumors
This Phase 1/2 trial tests IMP9064, either alone or with another treatment, in people with advanced solid cancers that have stopped responding to standard care. It aims to see how well it works and how safe it is, including whether it can be used when treatment options are limited.
Hackensack, New JerseyAges 18 years+ - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Scottsdale, ArizonaAges 18 years+ - NCT05270200RecruitingPhase 1/Phase 2
Azacitidine and chidamide after transplant to prevent AML relapse
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
Guanzhou, GuandongAges 18–60 - NCT05270096Recruiting
Matches children and young people to leukemia treatment plans
This trial is set up to review tumor lab test results to help doctors choose the most appropriate next treatment for people with leukemia that has returned or did not respond. It mainly matters for younger patients who are not already on a standard treatment path.
GhentAges birth–25 years - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+ - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05272293RecruitingPhase 1/Phase 2
Immunotherapy using donor immune cells for young people with AML
This trial tests a new cancer treatment made from a close family member’s immune cells, adjusted in the lab and given to children or young adults with AML. It may help the immune system better attack leukemia, especially for high-risk, relapsed, or refractory AML.
Minsk, Minsk OblastAges 6 months–30 years
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,669 recruiting oncology studies from the U.S. registry right now, out of 31,797 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.